Study · Randomized controlled trial · n = 835 · 2016

10 results

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.

Ahrén B, Hirsch IB, Pieber TR, Mathieu C, Gómez-Peralta F, Hansen TK, Philotheou A, Birch S, Christiansen E, Jensen TJ, Buse JB

Diabetes care4 Aug 2016Cited by 212 (Europe PMC)

PMID27493132DOI10.2337/dc16-0690PepBankPUB-27493132

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, liraglutide significantly reduced the daily insulin dose versus placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide lowered the daily insulin dose more than placebo.
Peptide
Liraglutide
Outcome
DecreaseDaily insulin dose
Study
n = 835
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6-1.8 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Significant reductions in daily insulin dose and increases in quality of life were seen with liraglutide versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin.
Report a problemFND-2749313207
02HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, liraglutide significantly increased quality of life versus placebo.
In plain wordsIn adults with type 1 diabetes, quality of life increased more with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseQuality of life
Study
n = 835
Comparator
Placebo
Outcome group
Exercise and physical function · Whole body
Studied dose
0.6-1.8 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Significant reductions in daily insulin dose and increases in quality of life were seen with liraglutide versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin.
Report a problemFND-2749313208
03HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on capped insulin, liraglutide 1.8 mg lowered HbA1c more than placebo at week 26.
In plain wordsIn adults with type 1 diabetes, liraglutide 1.8 mg lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at week 26
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−0.33%
liraglutide 1.8 mg
HbA1c change
0.01%
placebo
Source sentences
Summary
Mean baseline glycated hemoglobin (HbA1c) (8.1% [65.0 mmol/mol]) was significantly decreased with liraglutide versus placebo at week 26 (1.8 mg: -0.33% [3.6 mmol/mol]; 1.2 mg: -0.22% [2.4 mmol/mol]; 0.6 mg: -0.23% [2.5 mmol/mol]; placebo: 0.01% [0.1 mmol/mol]).
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin.
Report a problemFND-2749313201
04HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on capped insulin, liraglutide 1.2 mg lowered HbA1c more than placebo at week 26.
In plain wordsIn adults with type 1 diabetes, liraglutide 1.2 mg lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at week 26
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−0.22%
liraglutide 1.2 mg
HbA1c change
0.01%
placebo
Source sentences
Summary
Mean baseline glycated hemoglobin (HbA1c) (8.1% [65.0 mmol/mol]) was significantly decreased with liraglutide versus placebo at week 26 (1.8 mg: -0.33% [3.6 mmol/mol]; 1.2 mg: -0.22% [2.4 mmol/mol]; 0.6 mg: -0.23% [2.5 mmol/mol]; placebo: 0.01% [0.1 mmol/mol]).
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin.
Report a problemFND-2749313202
05HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on capped insulin, liraglutide 0.6 mg lowered HbA1c more than placebo at week 26.
In plain wordsIn adults with type 1 diabetes, liraglutide 0.6 mg lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at week 26
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−0.23%
liraglutide 0.6 mg
HbA1c change
0.01%
placebo
Source sentences
Summary
Mean baseline glycated hemoglobin (HbA1c) (8.1% [65.0 mmol/mol]) was significantly decreased with liraglutide versus placebo at week 26 (1.8 mg: -0.33% [3.6 mmol/mol]; 1.2 mg: -0.22% [2.4 mmol/mol]; 0.6 mg: -0.23% [2.5 mmol/mol]; placebo: 0.01% [0.1 mmol/mol]).
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin.
Report a problemFND-2749313203
06HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on capped insulin, liraglutide 1.8 mg reduced body weight versus placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide 1.8 mg reduced body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Body weight change
−5.1 kg
liraglutide 1.8 mg
Body weight change
−0.2 kg
placebo
Source sentences
Summary
Liraglutide significantly reduced mean body weight (-5.1, -4.0, and -2.5 kg for 1.8, 1.2, and 0.6 mg, respectively) versus placebo (-0.2 kg).
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin.
Report a problemFND-2749313204
07HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on capped insulin, liraglutide 1.2 mg reduced body weight versus placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide 1.2 mg reduced body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Body weight change
−4 kg
liraglutide 1.2 mg
Body weight change
−0.2 kg
placebo
Source sentences
Summary
Liraglutide significantly reduced mean body weight (-5.1, -4.0, and -2.5 kg for 1.8, 1.2, and 0.6 mg, respectively) versus placebo (-0.2 kg).
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin.
Report a problemFND-2749313205
08HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on capped insulin, liraglutide 0.6 mg reduced body weight versus placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide 0.6 mg reduced body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Body weight change
−2.5 kg
liraglutide 0.6 mg
Body weight change
−0.2 kg
placebo
Source sentences
Summary
Liraglutide significantly reduced mean body weight (-5.1, -4.0, and -2.5 kg for 1.8, 1.2, and 0.6 mg, respectively) versus placebo (-0.2 kg).
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin.
Report a problemFND-2749313206
09HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes, symptomatic hypoglycemia was more frequent with liraglutide 1.2 mg than with placebo.
In plain wordsIn adults with type 1 diabetes, low blood sugar with symptoms happened more often with liraglutide 1.2 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseSymptomatic hypoglycemia rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.2 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Symptomatic hypoglycemia
21.3 events/patient/year
liraglutide 1.2 mg
Symptomatic hypoglycemia
16.6 events/patient/year
placebo
Source sentences
Summary
There were higher rates of symptomatic hypoglycemia (21.3 vs. 16.6 events/patient/year; P = 0.03) with liraglutide 1.2 mg vs. placebo and of hyperglycemia with ketosis >1.5 mmol/L with liraglutide 1.8 mg vs. placebo (0.5 vs. 0.1 events/patient/year; P = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin.
Report a problemFND-2749313209
10HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes, hyperglycemia with ketosis was more frequent with liraglutide 1.8 mg than with placebo.
In plain wordsIn adults with type 1 diabetes, high blood sugar with ketones happened more often with liraglutide 1.8 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseHyperglycemia with ketosis rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.8 mg once daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Hyperglycemia with ketosis
0.5 events/patient/year
liraglutide 1.8 mg
Hyperglycemia with ketosis
0.1 events/patient/year
placebo
Source sentences
Summary
There were higher rates of symptomatic hypoglycemia (21.3 vs. 16.6 events/patient/year; P = 0.03) with liraglutide 1.2 mg vs. placebo and of hyperglycemia with ketosis >1.5 mmol/L with liraglutide 1.8 mg vs. placebo (0.5 vs. 0.1 events/patient/year; P = 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin.
Report a problemFND-2749313210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 2 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 3NCT06894784

A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

McGill University Health Centre/Research Institute of the McGill University Health Centren = 36est. Apr 2025 to est. Jan 2027

Diabetes Type 1

Trial page ClinicalTrials.govUpdated 30 Mar 2025

RecruitingPhase 2NCT05478707

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

AdventHealth Translational Research Instituten = 475 Oct 2023 to est. 30 Jul 2028

Diabetes Mellitus, Type 1 · Endothelial Dysfunction

Trial page ClinicalTrials.govUpdated 15 Oct 2026

CompletedPhase 3Results postedNCT02098395

The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

Novo Nordisk A/Sn = 835May 2014 to Apr 2015

Diabetes · Diabetes Mellitus, Type 1

Trial page ClinicalTrials.govUpdated 9 Feb 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.